This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Love, R. R. Articles by Cleary, J. F. Search for Related Content PubMed PubMed Citation Articles by Love, R. R. Articles by Cleary, J. F.

Endocrine Effects of Tamoxifen Plus Exemestane in Postmenopausal Women with Breast Cancer

Departments of ¹ Medicine, ² Biostatistics and Medical Informatics, and ³ School of Pharmacy, University of Wisconsin, Madison, Wisconsin

Requests for reprints: Richard R. Love, Department of Medicine, University of Wisconsin, 610 Walnut Street, 256 Warf Office Building, Madison, WI 53726-2397. Phone: 608-263-7066; Fax 608-263-4497; E-mail: rrlove{at}facstaff.wisc.edu.

Purpose: In some specific circumstances, combined hormonal therapies for breast cancer seem to be more effective than single maneuvers. In two laboratory mammary cancer models, the combination of the aromatase inactivator exemestane plus tamoxifen gives a higher response rate than is found with either agent alone.

To evaluate the endocrine effects of the combination of exemestane and tamoxifen, we studied 33 postmenopausal women disease-free following primary treatments for breast cancer who were taking tamoxifen for at least 3 months.

Design: After observation for symptoms on tamoxifen for 4 weeks, blood samples were taken and patients were begun additionally on exemestane 25 mg p.o. qd. Eight weeks later, blood samples were again taken, and exemestane was discontinued.

Results: A decrease in alkaline phosphatase was found with exemestane treatment (P = 0.06), whereas no change in osteocalcin level was observed. A decrease in high-density lipoprotein cholesterol level was found (P = 0.0025), whereas total cholesterol, low-density lipoprotein cholesterol and triglyceride levels showed no changes with exemestane treatment. Estradiol, estrone, and estrone sulfate levels decreased to immeasurable or very low levels with exemestane treatment (all P < 0.001). No significant changes in frequencies of common drug-associated side effects, such as vasomotor symptoms or weight change, were found.

Conclusions: Based on the absence of adverse endocrine effects with the addition of exemestane to tamoxifen therapy observed in this study, further clinical evaluation of the efficacy of this combination is warranted.

Key Words: tamoxifen • exemestane • postmenopausal • breast cancer

This article has been cited by other articles:

				B. Fisher, J. P. Costantino, D. L. Wickerham, R. S. Cecchini, W. M. Cronin, A. Robidoux, T. B. Bevers, M. T. Kavanah, J. N. Atkins, R. G. Margolese, et al. Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J Natl Cancer Inst, November 16, 2005; 97(22): 1652 - 1662. [Abstract] [Full Text] [PDF]